CoChat

Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®

Open access

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

As biosimilars enter the market, comparisons of product quality are needed. Manufacturing differences may lead to differences in critical quality attributes, which affect efficacy. Therefore, critical quality attributes (structure and biological activity) of Remicade® and of 2 biosimilar products (Flixabi®/Renflexis® and Remsima®/Inflectra®) were determined. We assessed binding to tumor necrosis factor in a fluorescence competitive binding assay; potency in a luciferase reporter gene assay; percentages of galactosylated glycan, afucose plus high mannosylated glycans, and charged glycan; FcγRIIIa (CD16) binding (assessed by 3 methods); and antibody-dependent cell-mediated cytotoxicity (ADCC) in the NK92-CD16a cell line and in peripheral blood mononuclear cells (PBMC). The results of Fab-related activity were similar for all products. Compared with Remicade®, Flixabi® had a lower percentage of charged glycan, and Remsima® had a higher percentage of galactosylated glycan and a lower percentage of afucose plus high mannosylated glycans. Whereas Remsima® and Remicade® are expressed in a Sp2/0 cell line, Flixabi® is expressed in a CHO cell line. Despite this difference, galactosylated glycans from the 3 products were not correlated with the expression system. The results of all 3 methods used in this study indicated that FcγRIIIa binding was lower with Remsima® than with Remicade®. The percentage of ADCC in NK92-CD16a cells was lower with Remsima® and higher with Flixabi® compared with Remicade®, but was similar for all 3 products in PBMC. Surface expression of CD16 was 5.7-fold greater on NK92-CD16a cells than on PBMC. Combined percentages of afucosylated and high mannosylated glycans were positively correlated with FcγRIIIa binding and ADCC in NK92-CD16 cells, while no correlation was observed in PBMC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/19420862.2017.1337620

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. N-glycan profiles, %Galactosylated, %Afucosylated and %High Mannosylated, and %Charged levels of Remicade®, Flixabi®, and Remsima®. (A) N-glycan profiles of Remicade®, Flixabi®, and Remsima®. EU, emission unit. (B) Percentage of galactosylated glycans. (C) Percentage of afucose and high mannosylated glycans. (D) Percentage of charged glycans. Light color dots: Individual data; Dark color dots: Mean data with mean value and standard deviation; Bar: 95% confidence interval of mean.
Figure 1. N-glycan profiles, %Galactosylated, %Afucosylated and %High Mannosylated, and %Charged levels of Remicade®, Flixabi®, and Remsima®. (A) N-glycan profiles of Remicade®, Flixabi®, and Remsima®. EU, emission unit. (B) Percentage of galactosylated glycans. (C) Percentage of afucose and high mannosylated glycans. (D) Percentage of charged glycans. Light color dots: Individual data; Dark color dots: Mean data with mean value and standard deviation; Bar: 95% confidence interval of mean.CC BY-NC-ND · PubMed Central
Figure 2. FcγRIIIa binding activity of Remicade®, Flixabi®, and Remsima®. (A) Percentage of relative binding activity using surface plasmon resonance. (B) Percentage of relative binding activity using AlphaScreen. (C) Percentage of relative binding activity using fluorescence-activated cell sorting. Light color dots: Individual data; Dark color dots: Mean data with mean value and standard deviation; Bar: 95% confidence interval of mean.
Figure 2. FcγRIIIa binding activity of Remicade®, Flixabi®, and Remsima®. (A) Percentage of relative binding activity using surface plasmon resonance. (B) Percentage of relative binding activity using AlphaScreen. (C) Percentage of relative binding activity using fluorescence-activated cell sorting. Light color dots: Individual data; Dark color dots: Mean data with mean value and standard deviation; Bar: 95% confidence interval of mean.CC BY-NC-ND · PubMed Central
Figure 3. Antibody-dependent cell-mediated cytotoxicity of Remicade®, Flixabi®, and Remsima®. (A) CD16-positive cells (Count %) and mean fluorescence intensities (MFI) in CD3 negative populations from healthy donor peripheral blood mononuclear cells and NK92-CD16a cell line. APC, Allophycocyanin; APC-A, Area of APC detection. (B) Percentage of relative ADCC activity using a NK92-CD16a cell line. (C) Percentage of relative ADCC activity using PBMC from healthy human donors. Light color dots: Individual data; Dark color dots: Mean data with mean value and standard deviation; Bar: 95% confidence interval of mean.
Figure 3. Antibody-dependent cell-mediated cytotoxicity of Remicade®, Flixabi®, and Remsima®. (A) CD16-positive cells (Count %) and mean fluorescence intensities (MFI) in CD3 negative populations from healthy donor peripheral blood mononuclear cells and NK92-CD16a cell line. APC, Allophycocyanin; APC-A, Area of APC detection. (B) Percentage of relative ADCC activity using a NK92-CD16a cell line. (C) Percentage of relative ADCC activity using PBMC from healthy human donors. Light color dots: Individual data; Dark color dots: Mean data with mean value and standard deviation; Bar: 95% confidence interval of mean.CC BY-NC-ND · PubMed Central
Figure 4. Correlation between percentage afucose plus percentage high mannosylated (HM) glycans and Fc functions for Remicade®, Flixabi®, and Remsima®. (A) Correlation between %afucose plus %HM glycan and %relative FcγRIIIa binding activity. (B) Correlation between %afucose plus %HM glycan and %relative ADCC activity.
Figure 4. Correlation between percentage afucose plus percentage high mannosylated (HM) glycans and Fc functions for Remicade®, Flixabi®, and Remsima®. (A) Correlation between %afucose plus %HM glycan and %relative FcγRIIIa binding activity. (B) Correlation between %afucose plus %HM glycan and %relative ADCC activity.CC BY-NC-ND · PubMed Central
Figure 5. Fab-related TNF-α binding and TNF-α neutralization activities of Remicade®, Flixabi®, and Remsima®. (A) Percentage of relative binding activity assessed by fluorescence resonance energy transfer. (B) Percentage of relative potency measured by a luciferase reporter gene assay. Light color dots: Individual data; Dark color dots: Mean data with mean value and standard deviation; Bar: 95% confidence interval of mean.
Figure 5. Fab-related TNF-α binding and TNF-α neutralization activities of Remicade®, Flixabi®, and Remsima®. (A) Percentage of relative binding activity assessed by fluorescence resonance energy transfer. (B) Percentage of relative potency measured by a luciferase reporter gene assay. Light color dots: Individual data; Dark color dots: Mean data with mean value and standard deviation; Bar: 95% confidence interval of mean.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 2

  1. Janssen Biotech REMICADE® (infliximab). Titusville, NJ: Janssen Immunology; 2016 12 [accessed 2017 3 8]. http://www.remicade.com
  2. Bergelson S Biological methods for assessment of Fc effector function of antibodies and Fc-containing molecules [oral presentation]. Presented at: Biopharmaceuticals Emerging Best Practices Association's Fifth Annual Biological Assay Conference; 2012 September 27; Lisbon,Portugal [accessed 2017 3 8]. http://www.bebpa.org/wp-content/uploads/2012/11/Svetlana-Bergelson-BEBPA-2012-final.pdf

Cited by

See all 60

Metadata

Authors
Lee, C., Jeong, M., Lee, J. J., Seo, S., Cho, S. C., Zhang, W., & Jaquez, O.
Affiliations
  • Samsung Bioepis (South Korea) (KR)
  • Biogen (United States) (US)
  • Biogen (Switzerland) (CH)
Corresponding author
Lee, Changsoo
Venue
mAbs
Published
2017-06-22
Volume
9
Issue
6
Pages
968-977
ISSN
  • 1942-0862 (ISSN-L)
  • 1942-0870
OpenAlex
W2653070086
Cited by
57
References
16
Citations by year
2026: 3 · 2025: 3 · 2024: 2 · 2023: 4 · 2022: 2 · 2021: 9 · 2020: 9 · 2019: 14 · 2018: 11
FWCI
4.21
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • mAbs (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Samsung
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
Keywords
infliximab, biosimilars, Remsima, glycosylation, critical quality attributes, FcγRIIIa binding, antibody-dependent cellular cytotoxicity, natural killer cells, CHO cell expression, TNF-alpha inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®. https://app.cochat.ai/papers/10.1080/19420862.2017.1337620
The paper
Lee, C., Jeong, M., Lee, J. J., Seo, S., Cho, S. C., Zhang, W., & Jaquez, O. (2017). Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®. mAbs. https://doi.org/10.1080/19420862.2017.1337620

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.